| Year |
Citation |
Score |
| 2021 |
Kucinski A, Sarter M. Reduction of falls in a rat model of PD falls by the M1 PAM TAK-071. Psychopharmacology. PMID 33735392 DOI: 10.1007/s00213-021-05822-x |
0.308 |
|
| 2021 |
Sarter M, Avila C, Kucinski A, Donovan E. Make a Left Turn: Cortico-Striatal Circuitry Mediating the Attentional Control of Complex Movements. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33615556 DOI: 10.1002/mds.28532 |
0.315 |
|
| 2015 |
Kucinski A, Wersinger S, Stachowiak EK, Becker C, Lippiello P, Bencherif M, Stachowiak MK. The effects of varenicline on sensory gating and exploratory behavior with pretreatment with nicotinic or 5-HT3A receptor antagonists. Behavioural Pharmacology. 26: 217-26. PMID 25485645 DOI: 10.1097/Fbp.0000000000000122 |
0.653 |
|
| 2014 |
Sarter M, Albin RL, Kucinski A, Lustig C. Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. Experimental Neurology. 257: 120-9. PMID 24805070 DOI: 10.1016/j.expneurol.2014.04.032 |
0.313 |
|
| 2014 |
Kucinski A, Curl R, Miletich RS, Corso TD, Stachowiak EK, Stachowiak MK. The role of fibroblast growth factor (FGF) signaling on dopaminergic function in Parkinson's disease The Central Catecholaminergic System: Anatomy, Functions and Disorders. 143-156. |
0.498 |
|
| 2014 |
Miletich RS, Kucinski A, Narla S, Benson C, Wersinger S, Corso TD, Bencherif M, Stachowiak EK, Stachowiak MK. Schizophrenia and the dopaminergic system The Central Catecholaminergic System: Anatomy, Functions and Disorders. 157-177. |
0.64 |
|
| 2013 |
Kucinski A, Wersinger S, Stachowiak EK, Corso TD, Parry MJ, Zhang J, Jordan K, Letchworth S, Bencherif M, Stachowiak MK. Neuronal nicotinic receptor agonists ameliorate spontaneous motor asymmetries and motor discoordination in a unilateral mouse model of Parkinson's disease. Pharmacology, Biochemistry, and Behavior. 111: 1-10. PMID 23872135 DOI: 10.1016/j.pbb.2013.07.005 |
0.593 |
|
| 2013 |
Stachowiak MK, Kucinski A, Curl R, Syposs C, Yang Y, Narla S, Terranova C, Prokop D, Klejbor I, Bencherif M, Birkaya B, Corso T, Parikh A, Tzanakakis ES, Wersinger S, et al. Schizophrenia: a neurodevelopmental disorder--integrative genomic hypothesis and therapeutic implications from a transgenic mouse model. Schizophrenia Research. 143: 367-76. PMID 23231877 DOI: 10.1016/J.Schres.2012.11.004 |
0.688 |
|
| 2012 |
Bencherif M, Stachowiak MK, Kucinski AJ, Lippiello PM. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia. Medical Hypotheses. 78: 594-600. PMID 22336089 DOI: 10.1016/j.mehy.2012.01.035 |
0.695 |
|
| 2012 |
Kucinski A, Syposs C, Wersinger S, Bencherif M, Stachowiak MK, Stachowiak EK. α7 neuronal nicotinic receptor agonist (TC-7020) reverses increased striatal dopamine release during acoustic PPI testing in a transgenic mouse model of schizophrenia. Schizophrenia Research. 136: 82-7. PMID 22285656 DOI: 10.1016/J.Schres.2012.01.005 |
0.708 |
|
| 2012 |
Kucinski A, Wersinger S, Stachowiak EK, Radell M, Hesse R, Corso T, Parry M, Bencherif M, Jordan K, Letchworth S, Stachowiak MK. Unilateral 6-OHDA <i>th-fgfr1</i>(<i>tk-</i>) mouse model supports the role of FGFs in Parkinson’s disease and the effects of nicotine and L-DOPA on spontaneous motor impairments Health. 4: 1178-1190. DOI: 10.4236/Health.2012.431176 |
0.605 |
|
| 2011 |
Kucinski AJ, Stachowiak MK, Wersinger SR, Lippiello PM, Bencherif M. Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia. Current Pharmaceutical Biotechnology. 12: 437-48. PMID 21133847 DOI: 10.2174/138920111794480589 |
0.678 |
|
| 2009 |
Klejbor I, Kucinski A, Wersinger SR, Corso T, Spodnik JH, Dziewiatkowski J, MoryÅ› J, Hesse RA, Rice KC, Miletich R, Stachowiak EK, Stachowiak MK. Serotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis. Schizophrenia Research. 113: 308-21. PMID 19570652 DOI: 10.1016/J.Schres.2009.06.006 |
0.686 |
|
| 2009 |
Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA, Stachowiak EK, Stachowiak MK, Papke RL, Lippiello PM, Bencherif M. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochemical Pharmacology. 78: 803-12. PMID 19482012 DOI: 10.1016/J.Bcp.2009.05.030 |
0.678 |
|
| 2008 |
Kucinski A, Klejbor I, Wersinger S, Hesse R, Stachowiak E, Stachowiak M. [P1.68]: Disruption in the integrative FGF receptor signaling may serve as a common pathological mechanism for the diverse genetic defects linked to schizophrenia International Journal of Developmental Neuroscience. 26: 864-864. DOI: 10.1016/J.Ijdevneu.2008.09.118 |
0.624 |
|
| Show low-probability matches. |